Purple Biotech (PPBT) Retained Earnings (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Retained Earnings of -$171.2 million for Q1 2026, down 17.93% year-over-year from -$208.6 million in Q1 2025, and little changed quarter-over-quarter from -$171.1 million in Q4 2025.
Purple Biotech (PPBT) Retained Earnings (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Retained Earnings for 13 consecutive years, with -$171.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 17.93% year-over-year to -$171.2 million; the TTM figure through Mar 2026 stood at -$171.2 million (down 17.93% YoY), while the FY2025 annual figure was -$171.1 million, down 18.24% from the prior year.
- Retained Earnings steadied at -$171.2 million in Q1 2026 per PPBT's latest filing, from -$171.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$103.2 million in Q1 2022 and bottomed at -$171.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$136.1 million across 5 years, with a median of -$141.2 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings slipped 22.82% — and 2025, when it fell 1.82%.
- Purple Biotech's Retained Earnings stood at -$117.6 million in 2022, then fell by 16.91% to -$137.5 million in 2023, then decreased by 5.27% to -$144.7 million in 2024, then declined by 18.24% to -$171.1 million in 2025, then decreased by 0.05% to -$171.2 million in 2026.
- Business Quant data shows PPBT's Retained Earnings at -$171.2 million in Q1 2026, -$171.1 million in Q4 2025, and -$147.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | -170.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -171.17 Mn |
| Dec 31, 2025 | -171.08 Mn |
| Sep 30, 2025 | -147.53 Mn |
| Jun 30, 2025 | -146.23 Mn |
| Mar 31, 2025 | -145.15 Mn |
| Dec 31, 2024 | -144.69 Mn |
| Sep 30, 2024 | -144.28 Mn |
| Jun 30, 2024 | -143.62 Mn |
| Mar 31, 2024 | -141.22 Mn |
| Dec 31, 2023 | -137.45 Mn |
| Sep 30, 2023 | -132.63 Mn |
| Jun 30, 2023 | -127.59 Mn |
| Mar 31, 2023 | -122.45 Mn |
| Dec 31, 2022 | -117.57 Mn |
| Sep 30, 2022 | -111.56 Mn |
| Jun 30, 2022 | -106.74 Mn |
| Mar 31, 2022 | -103.20 Mn |
| Dec 31, 2021 | -95.91 Mn |
| Sep 30, 2021 | -90.83 Mn |
| Jun 30, 2021 | -87.70 Mn |